Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) had its price target upped by investment analysts at Cantor Fitzgerald from $300.00 to $315.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald‘s price objective would indicate a potential upside of 17.95% from the stock’s previous close.

ASND has been the topic of a number of other reports. Oppenheimer lifted their price target on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. TD Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. BMO Capital Markets reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Morgan Stanley cut their target price on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. Finally, Jefferies Financial Group cut their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Nineteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $306.25.

Ascendis Pharma A/S Trading Up 3.0%

NASDAQ ASND opened at $267.07 on Friday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a twelve month low of $188.07 and a twelve month high of $282.15. The company has a market cap of $16.66 billion, a price-to-earnings ratio of 20.72 and a beta of 0.40. The business’s fifty day moving average is $242.58 and its 200 day moving average is $239.65.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Insider Activity at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP raised its holdings in Ascendis Pharma A/S by 435.8% during the 3rd quarter. First Trust Advisors LP now owns 86,940 shares of the biotechnology company’s stock worth $19,807,000 after purchasing an additional 70,714 shares during the last quarter. Allianz SE increased its position in shares of Ascendis Pharma A/S by 219.4% during the third quarter. Allianz SE now owns 16,215 shares of the biotechnology company’s stock worth $3,694,000 after buying an additional 11,138 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $6,075,000. GW&K Investment Management LLC raised its stake in Ascendis Pharma A/S by 121.2% during the third quarter. GW&K Investment Management LLC now owns 564 shares of the biotechnology company’s stock worth $128,000 after buying an additional 309 shares during the last quarter. Finally, USS Investment Management Ltd raised its position in shares of Ascendis Pharma A/S by 21.0% in the 3rd quarter. USS Investment Management Ltd now owns 170,587 shares of the biotechnology company’s stock worth $38,878,000 after acquiring an additional 29,577 shares in the last quarter.

Ascendis Pharma A/S News Roundup

Investors following ASND have been watching these news items:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.